UBS Maintains Buy on Adient, Raises Price Target to $34

Benzinga Newsdesk www.benzinga.com Positive 76.2%

Neg 0% Neu 0% Pos 76.2%

UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and raises the price target from $33 to $34.

Comments

No comments yet. Be the first!